On October 3, 2022 TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) (NASDAQ: TCBPW), a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer, reported that management will be presenting at the Dawson James 7th Annual Small Cap Growth Conference and LD MICRO Main Event XV (Press release, TC Biopharm, OCT 3, 2022, View Source [SID1234621654]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

TC BioPharm management will host one-on-one meetings with institutional investors at these conferences. Meetings can be scheduled through the firm hosting each event or by contacting TC BioPharm directly at [email protected]

Upcoming Conferences

The Dawson James 7th Annual Small Cap Growth Conference

LD MICRO Main Event XV